The interleukin-6 -174G/C polymorphism and prostate cancer risk: A systematic review and meta-analysis

Urologia Internationalis

Volumn 88, Issue 4, 2012, Pages 447-453

  Zhang, Hongtuan ^a   Xu, Yong ^a   Li, Liang ^b   Liu, Ranlu ^a   Ma, Baojie ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Association; Genetic polymorphism; Interleukin 6; Meta analysis; Prostatic neoplasm

Indexed keywords

INTERLEUKIN 6;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COCHRANE LIBRARY; GENETIC POLYMORPHISM; HUMAN; MALE; MEDLINE; PRIORITY JOURNAL; PROSTATE CANCER; RACE; SYSTEMATIC REVIEW;

CHI-SQUARE DISTRIBUTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LINEAR MODELS; MALE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84862765769     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000335207     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Jemal A, Ward E, Brawley O, et al: Cancer statistics, 2011. CA Cancer J Clin 2011; 61: 212-236.
3. Shacter E, Weitzman SA: Chronic inflammation and cancer. Oncology 2002; 16: 217-226.
4. Mosser DM, Zhang X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226: 205-218.
5. Serefoglou Z, Yapijakis C, Nkenke E, et al: Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 2008; 44: 1093-1099.
6. Howell WM, Rose-Zerilli MJ: Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007; 137: 194-199.
7. Ogata A, Chauhan D, Teoh G, et al: IL-6 triggers cell growth via the Ras-dependent mitogen- activated protein kinase cascade. J Immunol 1997; 159: 2212-2221.
8. Hirano T: Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-284.
9. Yu KD, Di GH, Fan L, et al: Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat 2010; 122: 483-488.
10. Wu D, Zou YF, Xu XY, et al: The association of genetic polymorphisms with cerebral palsy: a meta-analysis. Dev Med Child Neurol 2011; 53: 217-225.
11. Valdes AM, Arden NK, Tamm A, et al: A meta- analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. Osteoarthritis Cartilage 2010; 18: 699-704.
12. Zhang J, Dhakal IB, Lang NP, et al: Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control 2010; 21: 1437-1444.
13. Dossus L, Kaaks R, Canzian F, et al: PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010; 31: 455-461.
14. Moore SC, Leitzmann MF, Albanes D, et al: Adipokine genes and prostate cancer risk. Int J Cancer 2009; 124:869-876.
15. Pierce BL, Biggs ML, DeCambre M, et al: C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009; 20: 1193-1203.
16. Kesarwani P, Ahirwar DK, Mandhani A, et al: Association between -174G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 2008; 27: 505-510.
17. Michaud DS, Daugherty SE, Berndt SI, et al: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525-4530.
18. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.